Next Article in Journal
ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
Next Article in Special Issue
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
Previous Article in Journal
Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers
Previous Article in Special Issue
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
 
 
Article

Article Versions Notes

Cancers 2021, 13(13), 3231; https://doi.org/10.3390/cancers13133231
Action Date Notes Link
article pdf uploaded. 28 June 2021 17:55 CEST Version of Record https://www.mdpi.com/2072-6694/13/13/3231/pdf-vor
article supplementary file uploaded. 28 June 2021 17:55 CEST - https://www.mdpi.com/2072-6694/13/13/3231#supplementary
article xml file uploaded 29 June 2021 10:14 CEST Original file -
article xml uploaded. 29 June 2021 10:14 CEST Update -
article pdf uploaded. 29 June 2021 10:14 CEST Updated version of record https://www.mdpi.com/2072-6694/13/13/3231/pdf-vor
article html file updated 29 June 2021 10:18 CEST Original file -
article xml file uploaded 6 July 2021 10:52 CEST Update -
article xml uploaded. 6 July 2021 10:52 CEST Update https://www.mdpi.com/2072-6694/13/13/3231/xml
article pdf uploaded. 6 July 2021 10:52 CEST Updated version of record https://www.mdpi.com/2072-6694/13/13/3231/pdf
article html file updated 6 July 2021 10:53 CEST Update -
article html file updated 27 July 2022 02:26 CEST Update https://www.mdpi.com/2072-6694/13/13/3231/html
Back to TopTop